Astra Aktiebolag

Other

Astrazeneca Ab

Lipum Ab

Lennart Gustav Lundberg

Olle Hernell

Jan Birger Tornell

Stig Lennart Hansson

Susanne Lindquist

Michael Edlund

Lars Gustav Blackberg

Olle Carl Hernell

Mats Olof Stromqvist

Mats Str&ouml;mqvist

Michael Dalrymple

It provides methods and pharmaceutical compositions comprising antagonists to the protein Bile Salt-Stimulated Lipase (BSSL) for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis. It further relates to pharmaceutical compositions comprising BSSL antagonists and their use in methods for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis. Suitable BSSL antagonists to be used according to the invention are BSSL antibodies.

Methods for treating juvenile arthritis with ant-bile salt-stimulated lipase (BSSL) antibodies

Methods for treating rheumatoid arthritis with anti-bile salt-stimulated lipase (BSSL) antibodies

The present invention relates to human bile salt-stimulated lipase (BSSL) obtainable from transgenic sheep. The invention further relates to transgenic sheep whose germ cells and somatic cells contain a recombinant nucleotide molecule comprising a nucleotide sequence encoding for human BSSL. The invention also relates to methods for producing said transgenic animals, as well as to methods for producing human BSSL derived from transgenic animals. In addition, the invention provides the use of compositions comprising BSSL in the treatment of diseases relating to exocrine pancreatic insufficiency, and for improvement of the utilization of dietary lipids in preterm born infants.

Expression methods

Flotation chair

The invention discloses nucleic acids encoding variant Bile Salt Stimulated Lipase (BSSL; EC 3.1.1.1). The encoded variant BSSL enzymes maintain catalytic activity but contain fewer glycosylation sites that full-length BSSL. This reduced glycosylation facilitates purification and characterization of recombinant BSSL proteins.

Nucleic acids encoding BSSL variants

The present invention relates to novel polypeptides which are variants of Bile Salt-Stimulated Lipase (BSSL; EC 3.1.1.1). It also relates to DNA molecules encoding the said polypeptides, and to subproducts comprising the said DNA molecules. The invention further relates to processes for producing the said BSSL variants and for producing transgenic non-human mammals capable of expressing the BSSL variants. Furthermore the invention relates to such transgenic animals as well as to infant formulas comprising milk from such transgenic animals. The invention also relates to pharmaceutical compositions comprising the said polypeptides; and the use of the said polypeptides and DNA molecules for the manufacture of medicaments.

Transgenic non-human mammals producing BSSL variants

Growing community of inventors

Billdal, Sweden

Lennart Gustav Lundberg